β-Heregulin impairs EGF induced PLC-γ1 signalling in human breast cancer cells.
暂无分享,去创建一个
J. Hengstler | T. Dittmar | K. Zänker | B. Niggemann | A. Adawy | Nadine Rommerswinkel | Silvia Keil
[1] A. Harris,et al. Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer , 2015, Oncotarget.
[2] T. Dittmar,et al. Cytosolic calcium measurements in renal epithelial cells by flow cytometry. , 2014, Journal of visualized experiments : JoVE.
[3] T. Dittmar,et al. Analysis of cell migration within a three-dimensional collagen matrix. , 2014, Journal of visualized experiments : JoVE.
[4] D. Klimstra,et al. EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer , 2014, International journal of cancer.
[5] J. Wulfkuhle,et al. An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models , 2013, Breast Cancer Research.
[6] M. Masu,et al. ErbB2 Dephosphorylation and Anti-Proliferative Effects of Neuregulin-1 in ErbB2-Overexpressing Cells; Re-evaluation of Their Low-Affinity Interaction , 2013, Scientific Reports.
[7] K. Pantel,et al. The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC‐γ1 signalling in breast cancer cell migration and dissemination , 2012, The Journal of pathology.
[8] K. Haglund,et al. The role of ubiquitylation in receptor endocytosis and endosomal sorting , 2012, Journal of Cell Science.
[9] J. Segall,et al. Phosphoinositide 3-kinase signaling is critical for ErbB3-driven breast cancer cell motility and metastasis , 2011, Oncogene.
[10] Haluk Resat,et al. Bmc Cell Biology Her/erbb Receptor Interactions and Signaling Patterns in Human Mammary Epithelial Cells , 2009 .
[11] M. Kazanietz,et al. Heregulin beta1 promotes breast cancer cell proliferation through Rac/ERK-dependent induction of cyclin D1 and p21Cip1. , 2008, The Biochemical journal.
[12] T. Dittmar,et al. The neurotransmitter GABA is a potent inhibitor of the stromal cell-derived factor-1alpha induced migration of adult CD133+ hematopoietic stem and progenitor cells. , 2007, Stem cells and development.
[13] Ian O Ellis,et al. Heregulin β1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells , 2007, Breast Cancer Research.
[14] M. Moasser,et al. Targeting HER proteins in cancer therapy and the role of the non-target HER3 , 2007, British Journal of Cancer.
[15] Lewis C. Cantley,et al. AKT/PKB Signaling: Navigating Downstream , 2007, Cell.
[16] A. Citri,et al. EGF–ERBB signalling: towards the systems level , 2006, Nature Reviews Molecular Cell Biology.
[17] J. Segall,et al. ErbB3-dependent motility and intravasation in breast cancer metastasis. , 2006, Cancer research.
[18] J. Menéndez,et al. αVβ3 integrin regulates heregulin (HRG)-induced cell proliferation and survival in breast cancer , 2005, Oncogene.
[19] A. Thor,et al. Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] F. Maurer,et al. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[21] Thomas Dittmar,et al. Induction of cancer cell migration by epidermal growth factor is initiated by specific phosphorylation of tyrosine 1248 of c‐erbB‐2 receptor via epidermal growth factor receptor , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[22] Stefano Iacobelli,et al. The mechanism involved in the regulation of phospholipase Cγ1 activity in cell migration , 2002, Oncogene.
[23] U. Landegren,et al. Protein detection using proximity-dependent DNA ligation assays , 2002, Nature Biotechnology.
[24] L. E. Johannessen,et al. Ubiquitination and proteasomal activity is required for transport of the EGF receptor to inner membranes of multivesicular bodies , 2002, The Journal of cell biology.
[25] Yosef Yarden,et al. Biology of HER2 and Its Importance in Breast Cancer , 2001, Oncology.
[26] S. Eccles. The Role of c-erbB-2/HER2/neu in Breast Cancer Progression and Metastasis , 2001, Journal of Mammary Gland Biology and Neoplasia.
[27] R. Tibshirani,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[28] G. Assmann,et al. c‐erbB‐2/EGFR as dominant heterodimerization partners determine a motogenic phenotype in human breast cancer cells , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[29] G. Carpenter,et al. The Role of Individual SH2 Domains in Mediating Association of Phospholipase C-γ1 with the Activated EGF Receptor* , 1999, The Journal of Biological Chemistry.
[30] A. Wells,et al. A Role for Phospholipase C-γ-mediated Signaling in Tumor Cell Invasion , 1999 .
[31] Alan Wells,et al. Effect of Epidermal Growth Factor Receptor Internalization on Regulation of the Phospholipase C-γ1 Signaling Pathway* , 1999, The Journal of Biological Chemistry.
[32] A. Lenferink,et al. Differential endocytic routing of homo‐ and hetero‐dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers , 1998, The EMBO journal.
[33] B. Geiger,et al. Alternative Intracellular Routing of ErbB Receptors May Determine Signaling Potency* , 1998, The Journal of Biological Chemistry.
[34] D. Polk,et al. Epidermal growth factor receptor-stimulated intestinal epithelial cell migration requires phospholipase C activity. , 1998, Gastroenterology.
[35] J. Schlessinger,et al. Activation of phospholipase Cγ by PI 3‐kinase‐induced PH domain‐mediated membrane targeting , 1998 .
[36] Y. Yarden,et al. The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand‐receptor interactions , 1997, FEBS letters.
[37] S. Rhee,et al. Regulation of Phosphoinositide-specific Phospholipase C Isozymes* , 1997, The Journal of Biological Chemistry.
[38] N. Hynes,et al. ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling , 1997, The EMBO journal.
[39] L. Cook,et al. A simplified method for Ca2+ flux measurement on isolated human B cells that uses flow cytometry , 1997, Clinical and diagnostic laboratory immunology.
[40] Y. Yarden,et al. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. , 1996, The EMBO journal.
[41] F. Waldman,et al. ERBB-2 (HER2/neu) gene copy number, p185HER-2 overexpression, and intratumor heterogeneity in human breast cancer. , 1995, Cancer research.
[42] D A Lauffenburger,et al. Intracellular Trafficking of Epidermal Growth Factor Family Ligands Is Directly Influenced by the pH Sensitivity of the Receptor/Ligand Interaction (*) , 1995, The Journal of Biological Chemistry.
[43] G. Carpenter,et al. Individual epidermal growth factor receptor autophosphorylation sites do not stringently define association motifs for several SH2-containing proteins. , 1994, The Journal of biological chemistry.
[44] A. Ullrich,et al. Presence of SH2 domains of phospholipase C gamma 1 enhances substrate phosphorylation by increasing the affinity toward the epidermal growth factor receptor. , 1992, The Journal of biological chemistry.
[45] A. Ullrich,et al. SH2 domains prevent tyrosine dephosphorylation of the EGF receptor: identification of Tyr992 as the high‐affinity binding site for SH2 domains of phospholipase C gamma. , 1992, The EMBO journal.
[46] T. Pawson,et al. The tyrosine phosphorylated carboxyterminus of the EGF receptor is a binding site for GAP and PLC‐gamma. , 1990, The EMBO journal.
[47] Joseph Schlessinger,et al. Signal transduction by receptors with tyrosine kinase activity , 1990, Cell.
[48] R. Roskoski. The ErbB/HER family of protein-tyrosine kinases and cancer. , 2014, Pharmacological research.
[49] A. Wells,et al. A role for phospholipase C-gamma-mediated signaling in tumor cell invasion. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.